Structure Therapeutics Q2 FY26 net loss widens to $106.16 million; R&D expenses rise to $100.06 million
Reuters2026/08/06 20:17- Structure Therapeutics posted a Q2 net loss of $106.16 million, widening from $61.66 million a year earlier.
- R&D expense climbed to $100.06 million from $54.71 million; G&A rose to $18.57 million from $15.74 million.
- Cash, cash equivalents and short-term investments fell to $1.34 billion as of June 30, 2026, from $1.45 billion at year-end 2025.
- First patients were dosed in the Phase 3 ACCOMPLISH-1 and -2 program for aleniglipron in chronic weight management.
- Initial Phase 1 ACCG-2671 SAD data and a MAD trial start are targeted for Q3 2026; ACCESS OLE topline 72-week data are also due Q3.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GBP/JPY Price Forecast: Sellers eye 214.00 after SMA break
Bank of Canada keeps rates unchanged for the seventh consecutive time: Tariff wars increase inflation risk, 63% of analysts bet on a shift to rate hikes in the first half of 2027
On September 2, the Bank of Canada held its overnight rate at 2.25% for the seventh consecutive time. However, as the US-Canada tariff war has escalated and inflation risks have intensified, the market has shifted to betting on a rate hike. Governor Macklem warned that trade frictions will threaten the sustainability of the recovery. 63% of analysts expect the Bank of Canada to raise rates in the first half of 2027, while market pricing has shifted from expectations of easing to preparing for tightening in a stagflation scenario.
Warren Buffett and Berkshire’s new CEO pick Alphabet to win AI buildout stakes
Crypto prices
More
